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ABSTRACT 
 
It is debated whether treating cancer patients in high-volume surgical centres can lead to 
improvement in outcomes, such as shorter length of hospital stay, decreased frequency and 
severity of postoperative complications, decreased re-admission, and decreased mortality.  
 
The dataset for this analysis was based on cancer registration and hospital discharge data 
and comprised information on 15,738 non-small cell lung cancer patients resident and 
diagnosed in England in 2006-2010 and treated by surgical resection. The number of lung 
cancer resections was computed for each hospital in each calendar year, and patients were 
assigned to a hospital volume quintile on the basis of the volume of their hospital. 
 
Hospitals with large lung cancer surgical resection volumes were less restrictive in their 
selection of patients for surgical management, and provided a higher resection rate to their 
geographical population. Higher volume hospitals had shorter length of stay and the odds of 
re-admission were 15% lower in the highest hospital volume quintile compared with the 
lowest quintile. Mortality risks were 1% after 30 days and 3% after 90 days. Patients from 
hospitals in the highest volume quintile had about half the odds of death within 30 days 
than patients from the lowest quintile. 
 
Variations in outcomes were generally small, but in the same direction, with consistently 
better outcomes in the larger hospitals. This gives support to the ongoing trend towards 
centralisation of clinical services, but service re-organisation needs to take account of not 
only the size of hospitals but also referral routes and patient access.  
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INTRODUCTION 
 
Lung cancer is one of the most frequent types of cancer and the leading cause of cancer 
death globally.[1, 2]  There has been notable progress in lung cancer prevention, as 
evidenced by declining incidence rates in males,[3] and treatment for lung cancer has 
become more active and more effective.[4-6] Surgical resection remains the preferred 
treatment option for medically fit patients with early-stage disease.[7-10]  
 
Lung cancer surgery is highly specialised and increasingly centralised.[5] There is evidence 
that patient survival is better when surgical care is provided by a multi-disciplinary team in 
hospitals with high-volume practices, and analysis of surgical data from England in patients 
diagnosed in 2004-2008 showed lower death rates in patients operated in large-volume 
hospitals.[11] It remains to be addressed whether treating patients in high-volume surgical 
centres can lead to improvement in other relevant outcomes, such as shorter length of 
hospital stay, decreased frequency and severity of postoperative complications, decreased 
re-admission to hospital, and improved patient experience and satisfaction. The present 
study extends earlier work on patients undergoing lung cancer surgery in England to 
examine other outcomes, specifically length of stay in hospital after lung cancer resection, 
and risks of re-admission and death within 30 and 90 days of surgery.  
 
METHODS 
 
Study population and main predictor variables 
 
The principles of data extraction and linkages were as described previously.[9, 11] The 
dataset for the analysis comprised information on 15,738 non-small cell lung cancer patients 
who were resident and diagnosed in England in 2006-2010 and treated by potentially 
curative surgical resection as part of their initial care. The majority of resections were 
lobectomy (85%); 10% were pneumonectomy and 5% were other procedures. This is a 
complete and population-based ascertainment of surgically treated lung cancer in the 
country. The number of lung cancer resections was computed for each hospital in each 
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calendar year, and patients were assigned to a hospital volume quintile on the basis of the 
volume of their hospital in the year of diagnosis. 
 
The geographical resection rate was computed as the resected proportion of all non-small 
cell lung cancer patients in each of 152 geographical primary care trust areas in the period 
2006-2010.[9]  
 
Covariates 
 
Sex and age were analysed as categorical variables (age categorised in five-year groups). 
Socio-economic status was characterised by the quintile of the income domain of the 
indices of multiple deprivation 2010 on the basis of the residential postcode of each lung 
cancer patient. Co-morbidity was characterised by a modified Charlson co-morbidity index 
on the basis of in-patient hospital discharge diagnoses, ignoring the contribution to the co-
morbidity index from cancer. Tumour TNM stage and histology were obtained from the 
National Cancer Registration Service and the National Lung Cancer Audit Dataset 
(LUCADA).[12] The recorded stage of resected patients is most often the post-operative 
pathological stage, and may have been further revised in the four months after surgery. 
Ethnicity was derived from the electronic patient record at hospitals in England in the 
Hospital Episodes Statistics dataset. 
 
Outcomes 
 
Outcome variables were the length of stay in hospital (in days) at the time of the surgical 
resection for lung cancer, re-admission as an in-patient to any hospital, regardless of the 
reason for admission, within 30 and 90 days among the patients who were discharged to 
their home after the lung cancer resection, and death within 30 and 90 days from the date 
of surgery. 
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Statistical analysis 
 
Length of hospital stay distribution was described by the means, and the means of log-
transformed values (called the ‘log-average’ length of stay). Length of stay was analysed in 
relation to hospital volume quintile and covariates by linear regression of log-transformed 
length of stay.  A two-level linear regression model was fitted with the individual patient as 
the lower level and a random effect of hospital as the higher level. The risks of re-admission 
and death were analysed in relation to hospital volume quintile with univariate and 
multivariate logistic regression analysis. Two-level logistic regression models were fitted 
with hospital as a random effect. The covariates that were used in adjusted analyses were: 
geographical resection rate, age, co-morbidity, performance status, stage, histology and 
ethnicity using categorical variables as described in Table 1. 
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Table 1. Overview of the study population of 15,738 patients operated for lung cancer in England, 2006-2010. Distributions of variables 
and cross tabulations of lung cancer surgical procedure volume quintile and the other variables. 
                                
            Hospital volume (quintile)           
            1   2   3   4   5   
                                
      N %   N % N % N % N % N % 
                                
Hospital volume 1 1-75 3190 20                       
Quintile, range 2 77-112 3230 21                       
  3 114-155 3026 19                       
  4 156-186 3189 20                       
  5 189-287 3103 20                       
                                
Geographical 1 1.6-8.1 1803 11   607 19 363 11 398 13 249 8 186 6 
resection rate 2 8.2-10.2 2570 16   642 20 557 17 655 22 334 10 382 12 
Quintile, range 3 10.2-12.0 3118 20   599 19 678 21 727 24 579 18 535 17 
  4 12.0-14.2 3611 23   469 15 822 25 743 25 830 26 747 24 
  5 14.2-23.9 4636 29   873 27 810 25 503 17 1197 38 1253 40 
            χ2(1)=538.2; p<0.0001     
   
  
                             
Sex Male   8572 54   1757 55 1781 55 1600 53 1753 55 1681 54 
  Female   7166 46   1433 45 1449 45 1426 47 1436 45 1422 46 
            χ2(1)=0.5; p=0.48       
   
  
                             
Age-group 0-44   1673 11   369 12 346 11 313 10 332 10 313 10 
  55-59   1561 10   351 11 333 10 309 10 300 9 268 9 
  60-64   2642 17   549 17 535 17 510 17 525 16 523 17 
  65-69   3082 20   603 19 593 18 608 20 620 19 658 21 
  70-74   3154 20   634 20 653 20 608 20 658 21 601 19 
  75-79   2448 16   485 15 520 16 477 16 498 16 468 15 
  80-84   1020 6   183 6 209 6 173 6 227 7 228 7 
  85+   158 1   16 1 41 1 28 1 29 1 44 1 
            χ2(1)=14.2; p=0.0002     
   
  
                             
Socio-economic 
status 1 Affluent 2383 15   451 14 425 13 479 16 497 16 531 17 
(quintile) 2   2907 18   582 18 631 20 558 18 575 18 561 18 
  3   3170 20   669 21 709 22 594 20 593 19 605 19 
  4   3468 22   770 24 706 22 669 22 665 21 658 21 
  5 Deprived 3810 24   718 23 759 23 726 24 859 27 748 24 
            χ2(1)=1.1; p=0.28 
 
    
   
  
                            
Comorbidity 
index 0   12874 82   2621 82 2655 82 2510 83 2575 81 2513 81 
  1   1980 13   397 12 393 12 364 12 417 13 409 13 
  2   577 4   126 4 117 4 98 3 123 4 113 4 
  3+   307 2   46 1 65 2 54 2 74 2 68 2 
            χ2(1)=4.1; p=0.04 
 
    
   
  
                            
Performance 
status 0   4618 29   885 28 900 28 856 28 946 30 1031 33 
  1   3751 24   722 23 685 21 629 21 818 26 897 29 
  2   659 4   109 3 91 3 106 4 165 5 188 6 
  3   117 1   22 1 19 1 21 1 33 1 22 1 
  4   18 0   3 0 3 0 2 0 7 0 3 0 
  NA   6575 42   1449 45 1532 47 1412 47 1220 38 962 31 
            χ2(20)=296.0; p<0.0001     
                                
Clinical stage 1A   2419 15   489 15 493 15 414 14 473 15 550 18 
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  1B   2793 18   520 16 588 18 536 18 542 17 607 20 
  2A   493 3   79 2 101 3 73 2 100 3 140 5 
  2B   1390 9   280 9 273 8 263 9 274 9 300 10 
  3A   1101 7   189 6 188 6 204 7 246 8 274 9 
  3B   476 3   91 3 95 3 89 3 103 3 98 3 
  4   417 3   92 3 70 2 63 2 92 3 100 3 
  NA   6649 42   1450 45 1422 44 1384 46 1359 43 1034 33 
            χ2(28)=179.3; p<0.0001     
                                
Histology Adeno   8223 52   1652 52 1675 52 1537 51 1747 55 1612 52 
  Squamous   5537 35   1092 34 1101 34 1102 36 1138 36 1104 36 
  Large cell   341 2   65 2 72 2 104 3 44 1 56 2 
  
Other 
spec.   89 1   21 1 21 1 18 1 13 0 16 1 
  NSCLC   952 6   231 7 244 8 163 5 136 4 178 6 
  NA   596 4   129 4 117 4 102 3 111 3 137 4 
            χ2(20)=90.6; p<0.0001     
                                
Ethnicity White   15196 97   3033 95 3086 96 2947 97 3113 98 3017 97 
  Asian   181 1   58 2 46 1 30 1 26 1 21 1 
  Black   136 1   38 1 42 1 18 1 16 1 22 1 
  Chinese   40 0   11 0 5 0 4 0 12 0 8 0 
  Mixed   29 0   11 0 5 0 3 0 3 0 7 0 
  Other   92 1   27 1 23 1 11 0 11 0 20 1 
  NA   64 0   12 0 23 1 13 0 8 0 8 0 
            χ2(24)=80.5; p<0.0001              
  
9 
 
RESULTS 
 
Patients 
 
Table 1 gives an overview of the study cohort of 15,738 lung cancer patients diagnosed in 
the period 2006-2010 in England and treated with surgical resection. 
 
Hospital volume in relation to covariates 
 
Table 1 shows the marginal distributions of the variables in the analysis, and cross-
tabulations between the quintile of lung cancer surgical procedure volume (the principal 
independent variable) and covariates. A high annual hospital volume was strongly 
associated with a high geographical resection rate (χ2=538.2; p<0.0001). There was no 
association between hospital volume and sex of the patient, but high-volume hospitals had 
a higher proportion of older patients (χ2=14.2; p=0.0002). There was no association with 
socio-economic status but there were slightly more co-morbid patients in high-volume 
hospitals (χ2=4.1; p=0.04). High-volume hospitals had more complete reporting of 
performance status and tumour stage than low-volume hospitals, and they used the 
unspecific histology code “Non-small cell lung cancer (NSCLC)” less frequently. Within the 
patients with non-missing performance status, the high-volume hospitals had a higher 
proportion of patients with poor performance status (2 or higher) (χ2=14.3; p=0.0002) 
(Appendix table).  
 
Hospital volume in relation to length of hospital stay 
 
Table 2 shows the length of stay in hospital during the hospitalisation where the lung cancer 
resection took place. The average length of stay was 9.82 days in the quintile with the 
lowest hospital volume and 9.35 days in the highest-volume quintile. The linear regression 
of log-transformed length of stay on hospital volume quintile suggested that the difference 
in length of stay was about 0.3 days between the extreme quintiles. This gradient was 
statistically significant with a negative slope (p=0.004). Adjustment for the covariates that 
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were associated with resection quintile (geographical resection rate, age, co-morbidity, 
performance status, stage, histology and ethnicity) made the regression slope marginally 
steeper, reflecting the more adverse case-mix of patients in high-volume hospitals. A two-
level adjusted regression model with the individual hospital as a random effect reduced the 
statistical significance of the association between hospital volume and length of hospital 
stay (data not shown). 
 
Table 2. Length of stay (LOS) in the hospital admission with lung cancer resection in relation to 
quintile of lung cancer surgical procedure. Regression of log-transformed LOS on hospital volume 
quintile.  
  Hospital volume (quintile)       
  All 1 2 3 4 5 
              
LOS mean, days 9.60 9.82 9.88 9.61 9.33 9.35 
              
LOS mean, days, log-average* 8.23 8.26 8.44 8.31 8.02 8.12 
              
LOS mean, days, predicted from regression   8.37 8.30 8.23 8.16 8.09 
    Test for trend in log LOS: p=0.004 
*The log-average LOS is exp(mean(log(LOS)))             
 
Hospital volume in relation to re-admission and mortality 
 
Table 3 shows the associations between hospital volume quintile and the risk of re-
admission as an in-patient to a hospital and the risk of mortality, each within 30 and 90 days 
of surgery. Patients operated in high-volume hospitals had lower re-admission risks (19% in 
quintile 5 vs. 22% in quintile 1 for 30-day readmission, p for trend over the five quintiles: 
p=0.08; and 44% vs. 47% for 90-day readmission, p<0.0001). Similarly, mortality risk were 
lower in high-volume hospitals (0.5% vs. 1.0% within 30 days, p=0.01; and 2.2% vs. 3.1% 
within 90 days, p=0.02). 
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Table 3. Proportions of the resected lung cancer patients with 30-day and 90-day readmission to hospital, and the 
proportions who died within 30 days and 90 days. Overall distributions and associations with quintile of lung cancer 
surgical resection volume. 
            Hospital volume quintile             
            1   2   3   4   5   
      N %   N % N % N % N % N % 
                                
Readmission, 30d N   12487     2477   2581   2392   2550   2487   
  Y   3106 20   680 22 607 19 610 20 610 19 599 19 
            χ2(1)=3.1; p=0.08          
                                
Readmission, 90d N   8440     1642   1654   1653   1780   1711   
  Y   6855 45   1450 47 1465 47 1301 44 1314 42 1325 44 
            χ2(1)=15.2; p<0.0001        
                                
Mortality, 30d N   15593     3157   3188   3002   3160   3086   
  Y   145 0.9   33 1.0 42 1.3 24 0.8 29 0.9 17 0.5 
            χ2(1)=6.5; p=0.01          
                                
Mortality, 90d N   15295     3092   3119   2954   3094   3036   
  Y   443 2.8   98 3.1 111 3.4 72 2.4 95 3.0 67 2.2 
            χ2(1)=6.0; p=0.02          
 
Table 4 shows the more detailed analyses of 30-day and 90-day readmission risks in relation to hospital 
volume quintile. Statistical adjustment for geographical resection rate, age, co-morbidity, performance 
status, stage, histology and ethnicity strengthened the associations between hospital volume and 30-day 
and 90-day readmission risks. Further allowance for the two-level structure of the data by fitting a random 
effect of individual hospital further strengthened the association with 30-day re-admission risk, but the 
association with 90-day readmission was much attenuated in the two-level model. 
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Table 4. Univariate and adjusted analyses of 30-day and 90-day risks of readmission to hospital, in relation to lung cancer surgical procedure volume quintile.       
                                                            
      Readmission in 30 days                   Readmission in 90 days                 
                                                            
      % OR1 95% CI   OR2 95% CI   OR3 95% CI     % OR1 95% CI   OR2 95% CI   OR3 95% CI   
                                                            
Hospital 1 1-75 22 1.00       1.00       1.00         47 1.00       1.00       1.00       
volume 2 77-112 19 0.86 0.76 - 0.97 0.85 0.75 - 0.96 0.86 0.75 - 0.99   47 1.00 0.91 - 1.11 1.01 0.91 - 1.12 0.90 0.79 - 1.02 
(quintile) 3 114-155 20 0.93 0.82 - 1.05 0.92 0.81 - 1.04 0.90 0.77 - 1.04   44 0.89 0.81 - 0.99 0.88 0.79 - 0.97 0.85 0.73 - 0.98 
(range) 4 156-186 19 0.87 0.77 - 0.98 0.85 0.75 - 0.96 0.85 0.73 - 0.99   42 0.84 0.76 - 0.92 0.82 0.74 - 0.90 0.88 0.76 - 1.03 
  5 189-287 19 0.88 0.78 - 0.99 0.85 0.75 - 0.96 0.82 0.69 - 0.97   44 0.88 0.79 - 0.97 0.84 0.76 - 0.94 0.93 0.78 - 1.10 
                                                            
Trend       χ2=3.1, p=0.08   χ2=5.2, p=0.02   χ2=4.6, p=0.03       χ2=15.2, p<0.0001 χ2=21.9, p<0.0001 χ2=0.7, p=0.40   
                                                            
OR1: Crude odds ratio.                                                       
OR2: Adjusted for geographical resection rate, age, co-morbidity, performance status, stage, histology and ethnicity.                     
OR3: Adjusted as OR2, and also allowing for variation in readmission between individual hospitals.                           
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Table 5 shows the detailed analyses of 30-day and 90-day mortality outcomes. For both endpoints, higher 
hospital volume was associated with lower risks of death, and this did not change much with adjustment 
for covariates or with the allowance for variation between hospitals.   
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Table 5. Univariate and adjusted analyses of 30-day and 90-day mortality risks, in relation to lung cancer surgical procedure volume quintile.             
                                                            
      Mortality in 30 days                     Mortality in 90 days                   
                                                            
      % OR1 95% CI   OR2 95% CI   OR3 95% CI     % OR1 95% CI   OR2 95% CI   OR3 95% CI   
                                                            
Hospital 1 1-75 1.0 1.00       1.00       1.00         3.1 1.00       1.00       1.00       
volume 2 77-112 1.3 1.26 0.80 - 1.99 1.23 0.77 - 1.96 1.26 0.75 - 2.11   3.4 1.12 0.85 - 1.48 1.12 0.85 - 1.49 1.15 0.85 - 1.56 
(quintile) 3 114-155 0.8 0.76 0.45 - 1.30 0.75 0.44 - 1.28 0.77 0.43 - 1.38   2.4 0.77 0.56 - 1.05 0.78 0.57 - 1.07 0.79 0.56 - 1.11 
(range) 4 156-186 0.9 0.88 0.53 - 1.44 0.87 0.52 - 1.46 0.84 0.47 - 1.50   3.0 0.97 0.73 - 1.29 0.94 0.70 - 1.26 0.95 0.68 - 1.31 
  5 189-287 0.5 0.53 0.29 - 0.95 0.52 0.29 - 0.95 0.50 0.25 - 1.01   2.2 0.70 0.51 - 0.95 0.66 0.48 - 0.91 0.67 0.46 - 0.96 
                                                            
Trend       χ2=6.5, p=0.01   χ2=6.2, p=0.01   χ2=4.3, p=0.04       χ2=6.0, p=0.02   χ2=7.8, p=0.005 χ2=4.8, p=0.03   
                                                            
OR1: Crude odds ratio.                                                       
OR2: Adjusted for geographical resection rate, age, co-morbidity, performance status, stage, histology and ethnicity.                     
OR3: Adjusted as OR2, and also allowing for variation in mortality between individual hospitals.                             
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DISCUSSION 
 
Interpretation of the results of adjusted analyses and two-level analyses 
 
The principal findings of these analyses are:  
 
1:  Hospitals with large lung cancer surgical resection volumes are less conservative in their selection of 
patients for surgical management, and they provide a higher resection rate to their geographical 
population. 
 
2:  With adjustment for case-mix, high-volume hospitals have shorter length of stay, with approximately 
0.3 days difference between the extreme quintiles of hospital volume. The error of this estimate is large, 
however, particularly when the two-level structure of the data is considered. 
  
3:  Re-admission risks are high after lung cancer resection (20% and 45% are readmitted as in-patients to 
hospital within 30 and 90 days, respectively).  The odds of re-admission are about 15% lower in the highest 
hospital volume quintile compared with the lowest quintile. The estimated 30-day re-admission risk is not 
influenced by clustering of this outcome within individual hospitals, but the variation in 90-day readmission 
risk has a large contribution from the level of the individual hospital. 
 
4:  Overall mortality risks after lung cancer resection are 1% after 30 days and 3% after 90 days. Patients 
from hospitals in the highest volume quintile have about half the odds of death within 30 days than 
patients from the lowest quintile. For 90-day mortality the corresponding odds ratio is 0.7.  
 
The results suggest that there are systematic differences between smaller and larger hospitals that 
facilitate better patient outcomes in the larger hospitals, despite their more inclusive criteria for selection 
and the resulting adverse case-mix. In addition, it seems that the culture of data collection is better in the 
larger hospitals where completeness of recording of stage and performance status is highest. Other 
variations, not currently captured in the cancer register, may be availability of staging methods (e.g. 
endoscopic ultrasound and PET scanning) and the systematic use of adjuvant chemotherapy. 
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Comparison with other studies 
 
The analyses of 30-day and 90-day mortality risks in relation to hospital volume are consistent with 
previous analyses of hazard ratios for death.[11] The analyses of mortality outcomes in lung cancer 
patients in England in relation to surgical procedure volume adds to the growing body of evidence of 
favourable outcomes in high-volume hospital settings.[11, 13-16] It is noteworthy that the 30-day mortality 
outcome is insufficient to capture the full mortality effect, and that 90-day mortality is more than three 
times the magnitude of 30-day mortality (2.8% vs. 0.9%). Similar findings were reported in a large study in 
the USA.[17] This emphasises that mortality outcomes should be considered both in the short and the 
longer term.[11] 
 
The results for length of stay and re-admission emphasise that these outcomes vary along the gradient 
from low hospital volume (and high mortality) to high volume (and lower mortality). Recent studies have 
explored associations within the wider set of outcomes: hospital volume, length of stay, complications, re-
admission, mortality, and cost.[17-30] The emerging pattern is one of correlated and consistently 
favourable outcomes in high-volume hospitals. We are not aware of any studies of patient-reported 
outcomes and patient experience in relation to hospital volume, which should be an area for further 
research.  
 
 
Threshold of effects? 
 
It has been considered whether the associations with hospital volume would be characterised by a 
threshold above which increasing hospital volume would not provide any further increase in clinical 
benefit.[31] The present analysis was not designed to establish a threshold value. We consider that such 
analysis should pre-specify the hypothetical threshold value, and then proceed similarly to a formal 
equivalence trial.[32] Regardless, the present data suggests that there may well be different thresholds (if 
any) for different outcomes. Length of hospital stay and re-admission risks are numerically similar in 
quintiles 4 and 5 (i.e. above a possible threshold around 150 procedures per year), but in the analysis of 
mortality risks the data would suggest continued increase in benefit above around 190 procedures per 
year. 
 
The structure of health care systems and models of care vary between countries, and it is not necessarily 
the case that associations with procedure volume would be similar between countries or that any 
17 
 
thresholds would be the same. For example, the large study of lung cancer resection in the USA[17] 
considered 90 procedures per year as the cut-off point for their high-volume group of patients, but this 
falls within the second quintile in the present data and would be considered as a low volume in England. 
 
Strengths and limitations 
 
The present analysis benefit from systematically collected data with uniform standards and classifications 
in a large national population. The quality and completeness of cancer registration data in England have 
improved in recent years, and tumour stage is now available in the majority of cases. Ascertainment of 
outcomes is based on routinely collected data and unlikely to differ artifactually between hospitals with 
different practice volume. However, the use of routinely collected data is also the main limitation of the 
study, and information on co-morbidity, performance status and histology are subject to a higher degree of 
error than we would expect from a smaller study based on more fully quality-assured clinical data. 
 
The 30 and 90-day re-admission rates are remarkably high regardless of which type of hospital treated the 
patients. The data does not define why the patients were re-admitted, which may be for reasons other 
than for management of post-operative complications. 
 
We note that a high number of hospitals contribute to this data set. The record linkages identified the 
combination of lung cancer registration and a relevant surgical resection in patients with resection 
reported from 78 hospitals, but these resections should mainly or entirely take place in the 30 thoracic 
centres in England.[6] The data set includes a number of hospitals that contributed only a single or a few 
records to the data set. We have no means of quality assuring these records which for a large part may be 
due to errors of coding and registration. These hospitals with very few resections are all in quintile 1 of the 
hospital procedure volume grouping, and make up a small proportion of the 3190 patients in this group. 
We can judge the magnitude and direction of possible bias from the inclusion of these records by looking 
at associations across quintiles 2-4. Such restriction strengthens the association with length of stay (Table 
2) and with mortality (Table 5), and it has little or no impact on the analysis of readmission risks (Table 4). 
 
These findings support the view that the principal problem is too few lung cancer patients gaining access to 
a thoracic surgical service. The ultimate validation of this conjecture may require the collection of more 
detailed information on patient preferences, local clinical policies and decision making processes than are 
available in the routine cancer registration system. 
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Are the observed differences clinically relevant?  
 
We have described differences in bed-days, readmissions and deaths in terms of a relative measure (the 
odds ratio), Chi-square measures of association, and associated p-values. These standard measures allow 
for testing of the a priori hypotheses of association, but tells us little about the clinical and practical 
relevance of the observed variations in outcomes. In order to address this we computed (from the data in 
Tables 2 and 3) the total counts of bed-days, readmissions and deaths, and the number and proportion of 
these that would have been avoided if the patients in hospital volume quintiles 1-4 had experienced the 
same (lower) bed-days and risks as the patients in quintile 5.  
 
In absolute terms, the strongest signal in these data is found for 30-day post-operative mortality. Of the 
145 deaths that were observed, 65 deaths (45%) would have been avoided if the 12,635 patients in 
quintiles 1-4 had experienced the low 0.5% mortality risk of the 3103 patients in quintile 5. 
 
Similar calculations show that 24% of the 90-day post-operative deaths are attributable to the variation in 
90-day mortality between the quintiles, but for bed-days and readmissions, the proportions so attributable 
are only a few percent and each of these variations are not of practical relevance. It remains important 
that all the variations are in the same direction, with consistent better outcomes in high-volume hospitals. 
 
Crawford et al[33] looked at the socio-economic status of patients and the distance they lived both from 
the diagnostic and the surgical centre. Patients who lived far from the surgical centre had lower rate of 
surgery than those who lived closer to the centre. Likewise, Khakwani et al[6] showed that surgical centres 
with large catchment areas resected a high proportion of patients referred directly to the centre, but a 
smaller proportion of the patients referred to them from other hospitals. So, service re-organisation needs 
to take account of not only the size of hospitals but also referral routes and patient access.[34]  
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